Prognostic impact of HER-2 Subclonal Amplification in breast cancer

• Published in: Virchows Archiv : an international journal of pathology 2017-09, Vol.471 (3), p.313-319
• Main Authors: Di Oto, Enrico, Brandes, Alba A., Cucchi, Maria C., Foschini, Maria P.
• Format: Article
• Language: English
• Subjects: Adult; Aged; Aged, 80 and over; Amplification; Biomarkers, Tumor - analysis; Biomarkers, Tumor - genetics; Breast cancer; Breast carcinoma; Breast Neoplasms - genetics; Breast Neoplasms - mortality; Breast Neoplasms - pathology; Cancer; Consonants (speech); Criteria; ErbB-2 protein; Female; Gene Amplification; Genes, erbB-2 - genetics; Histology; Humans; Incidence; Lymphocytes B; Medical prognosis; Medicine; Medicine & Public Health; Metastases; Metastasis; Middle Aged; Monoclonal antibodies; Original Article; Pathology; Patients; Prognosis; Quality; Receptor, ErbB-2 - genetics; Retrospective Studies; Young Adult
• ISSN: 0945-6317; 1432-2307
• DOI: 10.1007/s00428-017-2151-x

The presence of a limited number of cells with HER-2 amplification (Subclonal Amplification) in breast carcinomas is occasionally encountered, but its prognostic impact is poorly known. The purpose of this study is to evaluate the prognostic impact of HER-2 Subclonal Amplification in a retrospective series of breast cancers. Accordingly, 81 consecutive breast carcinomas showing HER-2 Subclonal Amplification were obtained from the histology files (case series). These cases were subdivided into two groups: (a) those cases in which the HER-2 Subclonal Amplification was consonant to the accepted criteria for amplification, showing clusters of amplified cells, and (b) those cases with rare HER-2 Subclonal Amplification that did not reflect the accepted criteria for amplification, showing scattered amplified cells only. The incidence of metastases and late recurrences of the case series was compared with a series composed of 109 consecutive cases, being HER-2 homogeneous (comprising 14 Amplified and 95 Non-Amplified cases), matched for grade and stage (control series). It appeared that cases showing Subclonal Amplification had an incidence of metastases intermediate between the cases Amplified and Non-Amplified. Specifically, Subclonal Amplification with clustered cells had a lower incidence of metastases than Amplified cases (12.9 versus 21.4%). On the contrary, Subclonal Amplification with scattered cells showed an incidence of metastases higher than Non-Amplified cases (14 versus 9.47%). In addition, patients Subclonal Amplification with clustered cells, who were treated with the specific monoclonal antibody, had a lower incidence of metastases than patients showing Subclonal Amplification with scattered cells, who did not receive target therapy. These data, together with those recently published, indicate that Subclonal Amplification has an impact on prognosis and should be taken into consideration to correctly plan the treatment of breast cancer patients.